Vol. 17/No. 18 | Oncology Live®

September 26, 2016

The major advance of the MRI-guided radiotherapy system is the ability to visualize the lumpectomy cavity before and during the delivery of each treatment.

September 24, 2016

Although checkpoint blockade inhibitors targeting the PD-1/PD-L1 pathway are currently dominating the oncology community's attention, there are many other exciting approaches to anticancer immunotherapy being explored in a range of solid tumors

September 23, 2016

A genomic analysis of poorly differentiated neuroendocrine tumors from primary lung and gastrointestinal sites underscores the diversity of these tumors and the evolving need to move toward precision medicine when it comes to treating patients with these malignancies.

September 20, 2016

Approaches to reducing and preventing graft-versus-host-disease are being explored, including the development of ruxolitinib (Jakafi) and ibrutinib (Imbruvica) under breakthrough therapy designations.

September 20, 2016

Despite the fervent advocacy of stereotactic radiosurgery alone, the addition of whole-brain radiation therapy clearly improves local control, decreases distant brain failure, minimizes the need for salvage therapies such as surgery, and, most importantly, decreases neurologic death.

September 20, 2016

There are important ethical questions that must be fully considered when scientific research of any kind is conducted.

September 16, 2016

Fifty years after Henry Beecher’s landmark critique finally helped begin breaking the “code-of-silence” regarding the conduct of unethical clinical research in the United States—sadly including the oncology arena—many serious concerns linger.

September 15, 2016

Although lung cancer remains the leading cause of cancer-related mortality in the United States and 5-year survival rates are low at 17.8%, the grim picture for this tumor type is starting to shift to a more hopeful one as its biology is becoming better understood, facilitating treatment selection and providing researchers with new therapeutic targets.

September 14, 2016

Mark A. Rubin, MD, is an expert in prostate cancer genomics and pathology who has led key discoveries in the distinction between indolent and aggressive types of the malignancy.

September 13, 2016

Prostate cancer is slow-growing and readily curable in many cases, but the propensity for some tumors to develop into an aggressive, metastatic form that becomes resistant to androgen-targeting therapies continues to present a significant obstacle.